Literature DB >> 9054947

Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

D A Yergeau1, C J Hetherington, Q Wang, P Zhang, A H Sharpe, M Binder, M Marín-Padilla, D G Tenen, N A Speck, D E Zhang.   

Abstract

Acute myeloid leukaemia (AML) is a major haematopoietic malignancy characterized by the proliferation of a malignant clone of myeloid progenitor cells. A reciprocal translocation, t(8;21)(q22;q22), observed in the leukaemic cells of approximately 40% of patients with the M2 subtype of AML disrupts both the AML1 (CBFA2) gene on chromosome 21 and the ETO (MTG8) gene on chromosome 8 (refs 3-5). A chimaeric protein is synthesized from one of the derivative chromosomes that contains the N terminus of the AML1 transcription factor, including its DNA-binding domain, fused to most of ETO, a protein of unknown function. We generated mice that mimic human t(8;21) with a "knock-in' strategy. Mice heterozygous for an AML1-ETO allele (AML1-ETO/+) die in midgestation from haemorrhaging in the central nervous system and exhibit a severe block in fetal liver haematopoiesis. This phenotype is very similar to that resulting from homozygous disruption of the AML1 (Cbfa2) or Cbfb genes, indicating that AML1-ETO blocks normal AML1 function. However, yolk sac cells from AML1-ETO/+ mice differentiated into macrophages in haematopoietic colony forming unit (CFU) assays, unlike Cbfa2-/- or Cbfb-/-cells, which form no colonies in vitro. This indicates that AML1-ETO may have other functions besides blocking wild-type AML1, a property that may be important in leukaemogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054947     DOI: 10.1038/ng0397-303

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  100 in total

1.  Creating a transloxation. Engineering interchromosomal translocations in the mouse.

Authors:  G Testa; A F Stewart
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

2.  CBFB and MYH11 in inv(16)(p13q22) of acute myeloid leukemia displaying close spatial proximity in interphase nuclei of human hematopoietic stem cells.

Authors:  Allison B Weckerle; Madhumita Santra; Maggie C Y Ng; Patrick P Koty; Yuh-Hwa Wang
Journal:  Genes Chromosomes Cancer       Date:  2011-06-02       Impact factor: 5.006

3.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

4.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

5.  Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy.

Authors:  T Okuda; K Takeda; Y Fujita; M Nishimura; S Yagyu; M Yoshida; S Akira; J R Downing; T Abe
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

6.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Authors:  Yuki Kagiyama; Jiro Kitaura; Katsuhiro Togami; Tomoyuki Uchida; Daichi Inoue; Toshihiro Matsukawa; Kumi Izawa; Kimihito C Kawabata; Yukiko Komeno; Toshihiko Oki; Fumio Nakahara; Katsuaki Sato; Hiroyuki Aburatani; Toshio Kitamura
Journal:  Int J Hematol       Date:  2012-10-25       Impact factor: 2.490

8.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

Authors:  J Wang; T Hoshino; R L Redner; S Kajigaya; J M Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 9.  Runx1/AML1 in normal and abnormal hematopoiesis.

Authors:  Tetsuya Yamagata; Kazuhiro Maki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

10.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.